23andMe’s bankruptcy judge approved a $16.5 million settlement with its cyber insurers that transfers remaining policy value for the benefit of data breach victims. Judge Brian C. Walsh of the US ...

[indiscernible] of Citi Global Healthcare Conference. My name is Geoff Meacham, I'm the senior biopharma analyst here. We're thrilled today to have Regeneron. And speaking on behalf of Regeneron, we ...

When Carmen Thomas was growing up in Boston, her mom told her that her absent dad’s name was Joe Brown. So when she sent a saliva sample to 23andMe in her 20s and got a match with a Brown, she was ...

MLG Capital has appointed Kelly Whetstone, a compliance veteran with more than 20 years of financial services experience, as chief compliance officer and associate general counsel. National private ...

Jessica Presnall is joining the SEC from the Big 12, where over the course of a decade she received at least five promotions. A rising star in sports law has landed one of the plum jobs in college ...

Regeneron Pharmaceuticals is a leading biotech focused on gene editing. While the S&P 500 has dipped lower in November, Regeneron stock has climbed steadily higher. Despite its recent rise, Regeneron ...

FDA approved EYLEA HD for macular edema post-RVO with up to 8-week dosing after initial monthly doses. Phase 3 QUASAR trial showed non-inferior visual acuity gains with EYLEA HD compared to EYLEA.

After months of back-and-and forth with the FDA and a third-party manufacturer, Regeneron has secured two long-awaited approvals for Eylea HD, gaining a new indication and a more flexible dosing ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...

The approvals come as a pleasant surprise for Regeneron, analysts say, helping bolster the overall product profile of high-dose Eylea despite outstanding manufacturing concerns. Regeneron’s high-dose ...